Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Detroit, MI
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Detroit, MI
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Detroit, MI
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Detroit, MI
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Grand Rapids, MI
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Traverse City, MI
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Traverse City, MI
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Kansas City, MO
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Kansas City, MO
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Saint Louis, MO
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Great Falls, MT
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Great Falls, MT
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Great Falls, MT
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Great Falls, MT
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Las Vegas, NV
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Freehold, NJ
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Freehold, NJ
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Newark, NJ
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Newark, NJ
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Teaneck, NJ
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Teaneck, NJ
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
mi
from
Albuquerque, NM
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
mi
from
Albuquerque, NM
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Albany, NY
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Albany, NY
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Amherst, NY
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Amherst, NY
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Buffalo, NY
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Buffalo, NY
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Patchogue, NY
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Patchogue, NY
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Rochester, NY
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Rochester, NY
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Stony Brook, NY
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Stony Brook, NY
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Syracuse, NY
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Syracuse, NY
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Chapel Hill, NC
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Charlotte, NC
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Winston-Salem, NC
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Akron, OH
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Akron, OH
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Bellevue, OH
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Bellevue, OH
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Columbus, OH
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Columbus, OH
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Columbus, OH
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Columbus, OH
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Dayton, OH
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Dayton, OH
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Toledo, OH
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Toledo, OH
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Oklahoma City, OK
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Oklahoma City, OK
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Tulsa, OK
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Tulsa, OK
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Philadelphia, PA
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Philadelphia, PA
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Philadelphia, PA
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Spartanburg, SC
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Knoxville, TN
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Nashville, TN
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Nashville, TN
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Dallas, TX
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Houston, TX
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Houston, TX
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Round Rock, TX
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Round Rock, TX
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis
mi
from
San Antonio, TX
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis
mi
from
San Antonio, TX
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Sherman, TX
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Sherman, TX
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Salt Lake City, UT
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Alexandria, VA
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Alexandria, VA
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Charlottesville, VA
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Charlottesville, VA
Click here to add this to my saved trials
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Norfolk, VA
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Norfolk, VA
Click here to add this to my saved trials